JP2024525795A5 - - Google Patents
Info
- Publication number
- JP2024525795A5 JP2024525795A5 JP2024502029A JP2024502029A JP2024525795A5 JP 2024525795 A5 JP2024525795 A5 JP 2024525795A5 JP 2024502029 A JP2024502029 A JP 2024502029A JP 2024502029 A JP2024502029 A JP 2024502029A JP 2024525795 A5 JP2024525795 A5 JP 2024525795A5
- Authority
- JP
- Japan
- Prior art keywords
- cldn6
- seq
- rna
- composition
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2021/069869 | 2021-07-15 | ||
| EP2021069869 | 2021-07-15 | ||
| PCT/EP2022/069659 WO2023285560A1 (en) | 2021-07-15 | 2022-07-13 | Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525795A JP2024525795A (ja) | 2024-07-12 |
| JP2024525795A5 true JP2024525795A5 (enExample) | 2025-07-17 |
Family
ID=82781147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024502029A Pending JP2024525795A (ja) | 2021-07-15 | 2022-07-13 | Ｃｌｄｎ６陽性癌を治療するための、ｃｌｄｎ６およびｃｄ３結合要素をコードする薬剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250009780A1 (enExample) |
| EP (1) | EP4370551A1 (enExample) |
| JP (1) | JP2024525795A (enExample) |
| KR (1) | KR20240035794A (enExample) |
| CN (1) | CN117642429A (enExample) |
| AR (1) | AR126464A1 (enExample) |
| AU (1) | AU2022311053A1 (enExample) |
| CA (1) | CA3226700A1 (enExample) |
| IL (1) | IL309495A (enExample) |
| MX (1) | MX2024000678A (enExample) |
| TW (1) | TW202327647A (enExample) |
| WO (1) | WO2023285560A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4604995A1 (en) | 2022-10-17 | 2025-08-27 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| WO2025179238A2 (en) | 2024-02-23 | 2025-08-28 | BioNTech SE | Coronavirus vaccine |
| WO2025230946A1 (en) * | 2024-04-30 | 2025-11-06 | Modernatx, Inc. | T cell engagers and uses thereof |
| WO2026062193A1 (en) | 2024-09-20 | 2026-03-26 | BioNTech SE | Compositions and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2920209B1 (en) * | 2012-11-13 | 2020-08-05 | BioNTech SE | Agents for treatment of claudin expressing cancer diseases |
| IL282953B2 (en) * | 2012-11-13 | 2026-02-01 | Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh | Agents for the treatment of claudin-expressing cancers |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| WO2020191344A1 (en) * | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
-
2022
- 2022-07-13 IL IL309495A patent/IL309495A/en unknown
- 2022-07-13 JP JP2024502029A patent/JP2024525795A/ja active Pending
- 2022-07-13 CA CA3226700A patent/CA3226700A1/en active Pending
- 2022-07-13 EP EP22750715.9A patent/EP4370551A1/en active Pending
- 2022-07-13 WO PCT/EP2022/069659 patent/WO2023285560A1/en not_active Ceased
- 2022-07-13 MX MX2024000678A patent/MX2024000678A/es unknown
- 2022-07-13 KR KR1020247001508A patent/KR20240035794A/ko active Pending
- 2022-07-13 CN CN202280046768.5A patent/CN117642429A/zh active Pending
- 2022-07-13 TW TW111126241A patent/TW202327647A/zh unknown
- 2022-07-13 US US18/578,844 patent/US20250009780A1/en active Pending
- 2022-07-13 AU AU2022311053A patent/AU2022311053A1/en active Pending
- 2022-07-15 AR ARP220101862A patent/AR126464A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012314860B2 (en) | Immunocytokine combination therapy | |
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| KR20090021298A (ko) | 항-ｅｇｆｒ 항체의 동결건조 제제 | |
| JP2009518025A5 (enExample) | ||
| JP2024520666A5 (enExample) | ||
| IL298993A (en) | Therapeutic RNA for HPV positive cancer | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023545084A5 (enExample) | ||
| JP2019515904A (ja) | 新血管新生に関連する障害を治療するための組成物および方法 | |
| JP7379347B2 (ja) | プレクチン１結合抗体およびその使用 | |
| CN1345336A (zh) | 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途 | |
| Sun et al. | Progress in novel delivery technologies to improve efficacy of therapeutic antibodies | |
| JP2023524995A5 (enExample) | ||
| TW202535468A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2024537297A5 (enExample) | ||
| JP2024519904A5 (enExample) | ||
| WO2020131910A1 (en) | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a | |
| JP2019511567A5 (enExample) | ||
| CN101210048A (zh) | 用于靶向结合髓系白血病细胞的抗cd33的工程抗体及其表达载体和用途 | |
| JP2024537298A5 (enExample) | ||
| JP2024526860A (ja) | 初代ＮＫ細胞内での発現のためのキメラ抗原受容体ｍＲＮＡ分子の生成 | |
| JP2023550043A5 (enExample) | ||
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| TWI922217B (zh) | 用於治療類風濕性關節炎的抗體及其用途 | |
| HK40114150A (en) | Immunostimulatory mrna compositions and uses thereof |